Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

Stock Information for Enveric Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Enveric Biosciences Inc.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
Enveric Biosciences Announces Registration of Five Trademarks
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences Announces Patent Issuance

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.